Physician profile
Brandon C Clair
NPI 1528440856
$2,907.76
in general payments reported to CMS, 2019-2025
10 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.49 · 2020: $39.45 · 2021: $181 · 2022: $1,702 · 2023: $289 · 2024: $396 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,067.63 | 2020-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $389.99 | 2023-2025 | Purified Cortrophin Gel, Iluvien |
| Amgen INC. | $157.65 | 2024-2025 | Tepezza |
| Glaukos Corporation | $105.00 | 2024-2025 | Idosetr, Ce-Marked Kxla System |
| Abbvie INC. | $72.58 | 2023-2024 | Botox, Alphagan P, Lumigan |
| Mallinckrodt Hospital Products INC. | $35.74 | 2024 | Acthar |
| Tarsus Pharmaceuticals, INC. | $24.54 | 2025 | Xdemvy |
| Karl Storz Endoscopy-America | $21.35 | 2024 | Image1 S Connect |
| Thea Pharma INC. | $18.79 | 2025 | Iyuzeh |
| New World Medical,INC. | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.